Pyxis Oncology, Inc. (PYXS) Fair Value 2026

PYXS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (28/100)

Quick Summary — As of 2026-08-28, Pyxis Oncology, Inc. (PYXS) trades at $3.23. QOC: 5.0/10. Value Trap Risk: 28/100 (LOW). 0/13 models active.

Key Facts

Ticker
PYXS
Price
$3.23
Quality Score
5.0/10
Value Trap Risk
28/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 5.0/10 signals weak fundamentals

What Fair Value Does Each Model Give PYXS?

0 Intrinsic Value Models vs. Current Price ($3.23)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Pyxis Oncology, Inc. (PYXS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pyxis Oncology, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About PYXS?

0 of 13 models are currently active for PYXS. See which stocks rank higher →

How Does PYXS Rank in Biotechnology?

Among 625 Biotechnology stocks, PYXS ranks #323 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Pyxis Oncology, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is PYXS a Value Trap?

CirclFi's Value Trap algorithm assigns PYXS a score of 28/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Pyxis Oncology, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Pyxis Oncology, Inc. earns a quality score of 5.0/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PYXS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pyxis Oncology, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

IMRXImmuneering CorporationQOC 5.0KODKodiak Sciences Inc.QOC 5.0ABVCABVC BioPharma, Inc.QOC 5.0TCRTAlaunos Therapeutics, Inc.QOC 5.0SVRASavara Inc.QOC 5.0GNTAGenenta Science S.p.A.QOC 5.0PHIOPhio Pharmaceuticals Corp.QOC 4.4CGENCompugen Ltd.QOC 9.0NKTRNektar TherapeuticsQOC 5.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: IMRX · KOD · ABVC · TCRT · SVRA · GNTA · PHIO · CGEN · NKTR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PYXS?

6 companies across all industries closest to PYXS’s Quality of Company score of 5.0/10.

TNONTenon Medical, Inc.QOC 5.0SKYASkyAI, Inc.QOC 5.0FFLOFree Flow USA, Inc.QOC 5.0FVRFrontView REIT, Inc.QOC 5.0XPLSolitario Resources Corp.QOC 5.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TNON · SKYA · FFLO · FVR · XPL · NVDA

Where Does PYXS Sit in CirclFi's Biotechnology Rankings?

PYXS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Pyxis Oncology, Inc.’s Valuation?

What is Pyxis Oncology, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Pyxis Oncology, Inc. (PYXS). The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PYXS overvalued or undervalued right now?

At $3.23, 0 of 0 active models suggest PYXS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Pyxis Oncology, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.0 mean for PYXS?

Pyxis Oncology, Inc.'s QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PYXS?

CirclFi analyzes PYXS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is PYXS a value trap in 2026?

Pyxis Oncology, Inc.'s Value Trap score is 28/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Pyxis Oncology, Inc. (PYXS) a Quality of Company score of 5.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PYXS/ · Methodology
Primary sources for this PYXS valuation
  • Financial statements: Pyxis Oncology, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001782223) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PYXS as of ; valuations recomputed .